Sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists, and the risk of macrovascular, and microvascular complications among patients with type 2 diabetes and non-alcoholic fatty liver disease

被引：0
|
作者：
Bea, Sungho [1 ]
Filion, Kristian B. [2 ]
Shin, Ju-Young [1 ]
机构：
[1] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea
[2] McGill Univ, Montreal, PQ, Canada
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
58
引用
收藏
页码：14 / 15
页数：2
相关论文
共 50 条
  • [41] Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease
    Hofer, Felix
    Kazem, Niema
    Schweitzer, Ronny
    Hammer, Andreas
    Jakse, Friedrich
    Koller, Lorenz
    Hengstenberg, Christian
    Sulzgruber, Patrick
    Niessner, Alexander
    CARDIOVASCULAR DRUGS AND THERAPY, 2021, 35 (06) : 1161 - 1170
  • [42] Comparative safety and cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in nursing homes
    Riester, Melissa R.
    Zullo, Andrew R.
    Joshi, Richa
    Daiello, Lori A.
    Hayes, Kaleen N.
    Ko, Darae
    Kim, Dae Hyun
    Munshi, Medha
    Berry, Sarah D.
    DIABETES OBESITY & METABOLISM, 2024, 26 (08): : 3403 - 3417
  • [43] Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
    Sofogianni, Areti
    Filippidis, Athanasios
    Chrysavgis, Lampros
    Tziomalos, Konstantinos
    Cholongitas, Evangelos
    WORLD JOURNAL OF HEPATOLOGY, 2020, 12 (08) : 493 - 505
  • [44] Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
    Areti Sofogianni
    Athanasios Filippidis
    Lampros Chrysavgis
    Konstantinos Tziomalos
    Evangelos Cholongitas
    World Journal of Hepatology, 2020, 12 (08) : 493 - 505
  • [45] First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists A Cost-Effectiveness Study
    Choi, Jin G.
    Winn, Aaron N.
    Skandari, M. Reza
    Franco, Melissa, I
    Staab, Erin M.
    Alexander, Jason
    Wan, Wen
    Zhu, Mengqi
    Huang, Elbert S.
    Philipson, Louis
    Laiteerapong, Neda
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (10) : 1392 - +
  • [46] Comparing cardiovascular benefits of sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in older adults with diabetes
    Htoo, Phyo
    Buse, John
    Wang, Tiansheng
    Pate, Virginia
    Crowley, Matthew
    Sturmer, Til
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 138 - 139
  • [47] Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD
    Gregg, L. Parker
    Richardson, Peter A.
    Nambi, Vijay
    Petersen, Laura A.
    Matheny, Michael E.
    Virani, Salim S.
    Navaneethan, Sankar D.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2025, 36 (01): : 87 - 98
  • [48] Use of thiazolidinediones and glucagon-like peptide-1 receptor agonists and the risk of non-alcoholic fatty liver disease
    Driessen, Johanna H. M.
    van Dalem, Judith
    Burden, Andrea M.
    Stehouwer, Coen D. A.
    Klungel, Olaf H.
    de Vries, Frank
    Brouwers, Martijn C. G. J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 128 - 128
  • [49] Sodium-Glucose Cotransporter-2 Inhibitors versus Glucagon-Like Peptide 1 Receptor Agonists Effects on Kidney and Clinical Outcomes in Veterans with Type 2 Diabetes
    Morello, Candis M.
    Awdishu, Linda
    Lam, Stepfanie
    Heman, Amy
    Bounthavong, Mark
    KIDNEY360, 2024, 5 (11): : 1633 - 1643
  • [50] The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus
    Salmen, Teodor
    Bobirca, Florin-Teodor
    Bica, Ioana-Cristina
    Mihai, Doina-Andrada
    Pop, Corina
    Stoian, Anca Pantea
    LIFE-BASEL, 2023, 13 (03):
12345